Lithium carbonate in the management of cannabis withdrawal in humans: An open-label study

Journal of Psychopharmacology

Volumn 23, Issue 1, 2009, Pages 84-93

  Winstock, A R ^a,b,d   Lea, T ^a,b   Copeland, J ^c  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b SYDNEY SOUTH WEST AREA HEALTH SERVICE   (Australia)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

Cannabis; Dependence; Depression; Lithium; Withdrawal

Indexed keywords

CANNABIS; LITHIUM CARBONATE;

ADULT; AGGRESSION; ANGER; ANXIETY; APPETITE DISORDER; ARTICLE; CANNABIS ADDICTION; CHILL; CLINICAL ARTICLE; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIAGNOSTIC VALUE; DRUG DETOXIFICATION; DRUG SAFETY; EVENING DOSAGE; FEMALE; FOLLOW UP; HEADACHE; HUMAN; IRRITABILITY; MALE; MARIJUANA WITHDRAWAL CHECKLIST; MENTAL CONCENTRATION; MOOD DISORDER; MORNING DOSAGE; MUSCLE SPASM; NAUSEA; NERVOUSNESS; OPEN STUDY; PRIORITY JOURNAL; RESTLESSNESS; SCORING SYSTEM; SELF REPORT; SHIVERING; SLEEP DISORDER; STOMACH PAIN; SWEATING; UNPLEASANT DREAM; URINALYSIS; VALIDATION STUDY; WITHDRAWAL SYNDROME;

ADULT; ANTIDEPRESSIVE AGENTS; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HUMANS; LITHIUM CARBONATE; MALE; MARIJUANA ABUSE; PSYCHOMETRICS; SMOKING; SUBSTANCE WITHDRAWAL SYNDROME; TIME FACTORS; TREATMENT OUTCOME;

EID: 58649086695     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881108089584     Document Type: Article

References (60)

1. Aihw (2005) Alcohol and Other Drug Treatment Services in Australia 2003-04: Report on the National Minimum Data Set. Canberra: Australian Institute of Health and Welfare.
2. Beck, AT, Steer, RA, Brown, GK (1996) BDI-II Manual, second ed. San Antonio, TX: Psychological Corporation.
3. Bowden, CL (1998) Key treatment studies of lithium in manic-depressive illness: efficacy and side effects. J Clin Psychiatry 59: 35-36.
4. Bowen, R., McIlwrick, J., Baetz, M., Zhang, X. (2005) Lithium and marijuana withdrawal. Can J Psychiatry 50: 240-241.
5. Budney, AJ (2006) Are specific dependence criteria necessary for different substances: how can research on cannabis inform this issue ? Addiction 101: 125-133.
6. Budney, AJ, Hughes, JR (2006) The cannabis withdrawal syndrome. Curr Opin Psychiatry 19: 233-238.
7. Budney, AJ, Hughes, JR, Moore, BA, Novy, PL (2001) Marijuana abstinence effects in marijuana smokers maintained in their home environment. Arch Gen Psychiatry 58: 917-924.
8. Budney, AJ, Hughes, JR, Moore, BA, Vandrey, R. (2004) Review of the validity and significance of cannabis withdrawal syndrome. Am J Psychiatry 161: 1967-1977.
9. Budney, AJ, Moore, BA, Vandrey, RG, Hughes, JR (2003) The time course and significance of cannabis withdrawal. J Abnorm Psychol 112: 393-402.
10. Budney, AJ, Novy, PL, Hughes, JR (1999) Marijuana withdrawal among adults seeking treatment for marijuana dependence. Addiction 94: 1311-1322.
11. Budney, AJ, Vandrey, RG, Hughes, JR, Moore, BA, Bahrenburg, B. (2007) Oral delta-9-tetrahydrocannabinol suppresses cannabis withdrawal symptoms. Drug Alcohol Depend 86: 22-29.
12. Caswell, A, (ed) (2005) MIMS Annual 2005. CMPMedica, Sydney.
13. Copeland, J., Gilmour, S., Gates, P., Swift, W. (2005) The Cannabis Problems Questionnaire: factor structure, reliability, and validity. Drug Alcohol Depend 80: 313-319.
14. Copeland, J., Swift, W., Rees, V. (2001 a) Clinical profile of participants in a brief intervention for cannabis use disorder. J Subst Abuse Treat 20: 45-52.
15. Copeland, J., Swift, W., Roffman, R., Stephens, R. (2001 b) A randomized controlled trial of brief cognitive-behavioral interventions for cannabis use disorder. J Subst Abuse Treat 21: 55-64.
16. Copersino, M., Boyd, S., Tashkin, D., Huestis, M., Heishman, S., Dermand, J., Simmons, M., Gorelick, D. (2006) Cannabis withdrawal among non-treatment-seeking adult cannabis users. Am J Addict 15: 8-14.
17. Coppen, A., Abou-Saleh, M., Milln, P., Bailey, J., Wood, K. (1983) Decreasing lithium dosage reduces morbidity and side-effects during prophylaxis. J Affect Disord 5: 353-362.
18. Cui, S-S., Bowen, RC, Gu, G-B., Hannesson, DK, Yu, PH, Zhang, X. (2001) Prevention of cannabinoid withdrawal syndrome by lithium: involvement of oxytocinergic neuronal activation. J Neurosci 21: 9867-9876.
19. Degenhardt, L., Hall, W., Lynskey, M. (2003) Testing hypotheses about the relationship between cannabis use and psychosis. Drug Alcohol Depend 71: 37-48.
20. Dennis, M., Titus, J., White, M., Unsicker, J., Hodkgins, D. (2002) Global Appraisal of Individual Needs (GAIN). Administration Guide for the GAIN and Related Measures. Bloomington, IL: Chestnut Health Systems.
21. Derogatis, LR (1994) Symptom Checklist 90-R: Administration, Scoring and Procedures Manual, third ed. Minneapolis: NCS Pearson.
22. Didcott, P., Reilly, D., Swift, W., Hall, W. (1997) Long-term cannabis users on the New South Wales North Coast (Monograph 30). Sydney: National Drug and Alcohol Research Centre, University of New South Wales.
23. Fagerström, KO, Kunze, M., Schoberberger, R., Breslau, N., Hughes, JR, Hurt, R.D., Puska, P., Ramstrom, L., Zatonski, W. (1996) Nicotine dependence versus smoking prevalence: comparison among countries and categories of smokers. Tob Control 5: 52-56.
24. Fergusson, DM, Poulton, R., Smith, PF, Boden, JM (2006) Cannabis and psychosis. BMJ 332: 172-175.
25. Ferrier, IN, Ferrie, LJ, Macritchie, KA (2006) Old drug, new data: revisiting... lithium therapy. Advances in Psychiatric Treatment 12: 256-264.
26. Geddes, JR, Burgess, S., Hawton, K., Jamison, K., Goodwin, GM (2004) Long-term lithium therapy for bipolar disorder: systematic review and meta-analysis of randomized controlled trials. Am J Psychiatry 161: 217-222.
27. Gelenberg, AJ, Jefferson, JW (1995) Lithium tremor. J Clin Psychiatry 56: 283-287.
28. Gossop, M., Darke, S., Griffiths, P., Hando, J., Powis, B., Hall, W., Strang, J. (1995) The Severity of Dependence Scale (SDS). psychometric properties of the SDS in English and Australian samples of heroin, cocaine and amphetamine users. Addiction 90: 607-614.
29. Haney, M., Hart, CL, Vosburg, SK, Nasser, J., Bennett, A., Zubaran, C., Foltin, R.W. (2004) Marijuana withdrawal in humans: effects of oral THC or divalproex. Neuropsychopharmacology 29: 158-170.
30. Haney, M., Hart, CL, Ward, AS, Foltin, RW (2003) Nefazodone decreases anxiety during marijuana withdrawal in humans. Psychopharmacology 165: 157-165.
31. Haney, M., Ward, AS, Comer, SD, Foltin, RW, Fischman, MW (1999 a) Abstinence symptoms following oral THC administration to humans. Psychopharmacology 141: 385-394.
32. Haney, M., Ward, AS, Comer, SD, Foltin, RW, Fischman, MW (1999 b) Abstinence symptoms following smoked marijuana in humans. Psychopharmacology 141: 395-404.
33. Haney, M., Ward, AS, Comer, SD, Hart, CL, Foltin, RW, Fischman, MW (2001) Bupropion SR worsens mood during marijuana withdrawal in humans. Psychopharmacology 155: 171-179.
34. Heatherton, T., Kozlowski, L., Frecker, R., Fagerström, KO (1991) The Fagerström test for nicotine dependence: A revision of the Fagerström Tolerance Questionnaire. Br J Addict 86: 1119-1127.
35. Heinrichs, M., Baumgartner, T., Kirschbaum, C., Ehlert, U. (2003) Social support and oxytocin interact to suppress cortisol and subjective responses to psychosocial stress. Biol Psychiatry 54: 1389-1398.
36. Heinrichs, M., Gaab, J. (2007) Neuroendocrine mechanisms of stress and social interaction: implications for mental disorders. Curr Opin Psychiatr 20: 158-162.
37. Hides, L., Dawe, S., Kavanagh, DJ, Young, RM (2006) Psychotic symptom and cannabis relapse in recent-onset psychosis. Prospective study. Br J Psychiatry 189: 137-143.
38. Huestis, MA, Cone, EJ (1998) Differentiating new marijuana use from residual drug excretion in occasional marijuana users. J Anal Toxicol 22: 445-454.
39. Huestis, MA, Mitchell, JM, Cone, EJ (1995) Detection times of marijuana metabolites in urine by immunoassay and GC-MS. J Anal Toxicol 19: 443-449.
40. Insel, TR (1992) Oxytocin - a neuropeptide for affiliation: evidence from behavioral, receptor autoradiographic, and comparative studies. Psychoneuroendocrinology 17: 3-35.
41. Johnson, FN (1984) The History of Lithium Therapy. London: Mac-Millan Press.
42. Levin, FR, McDowell, D., Evans, SM, Nunes, E., Akerele, E., Donovan, S., Vosburg, SK (2004) Pharmacotherapy for marijuana dependence: a double-blind, placebo-controlled pilot study of Divalproex Sodium. Am J Addict 13: doi: 10.1080/10550490490265280.
43. Marijuana Treatment Project Research Group (2004) Brief treatments for cannabis dependence: findings from a randomized multisite trial. J Consult Clin Psychol 72: 455-466.
44. Mathers, C., Vos, T., Stevenson, C. (1999) The Burden of Disease and Injury in Australia. Canberra: Australian Institute of Health and Welfare.
45. McRae, AL, Brady, KT, Carter, RE (2006) Buspirone for treatment of marijuana dependence: a pilot study. Am J Addict 15: 404.
46. Price, LH, Heninger, GR (1994) Lithium in the treatment of mood disorders. N Engl J Med 331: 591-598.
47. Ratey, JJ, Ciraulo, DA, Shader, RI (1981) Lithium and marijuana. J Clin Psychopharmacol 1: 32-33.
48. Semple, DM, McIntosh, AM, Lawrie, SM (2005) Cannabis as a risk factor for psychosis: systematic review. J Psychopharmacol 19: 187-194.
49. Smith, NT (2002) A review of the published literature into cannabis withdrawal symptoms in human users. Addiction 97: 621-632.
50. Sobell, LC, Sobell, MB (1992). Timeline follow-back: a technique for assessing self-reported alcohol consumption. In: Litten, RZ, Allen, J, Towota, NJ, (eds), Measuring Alcohol Consumption: Psychosocial and Biological Methods. Totowa, NJ: Humana Press, pp. 41-72.
51. Sobell, LC, Sobell, MB, Buchan, G., Cleland, PA, Fedoroff, I., Leo, GI (1996) The reliability of the Timeline Followback method applied to drug, cigarette, and cannabis use. Presented at the 30th Annual Meeting of the Association for Advancement of Behaviour Therapy, New York.
52. Spielberger, CD (1999) State-Trait Anger Expression Inventory-2: Professional Manual. Lutz, FL: Psychological Assessment Resources.
53. Spielberger, CD, Gorsuch, RL, Lushene, R., Vagg, PR, Jacobs, GA (1983) Manual for the State-Trait Anxiety Inventory (Form Y Self-evaluation Questionnaire). Redwood City, CA: Mind Garden.
54. Swift, W., Copeland, J., Hall, W. (1998 a) Choosing a diagnostic cut-off for cannabis dependence. Addiction 93: 1681-1692.
55. Swift, W., Hall, W., Copeland, J. (1998 b) Characteristics of long-term cannabis users in Sydney, Australia. Eur Addict Res 4: 190-197.
56. Swift, W., Hall, W., Teesson, M. (2001) Cannabis use and dependence among Australian adults: results from the National Survey of Mental Health and Wellbeing. Addiction 96: 737-748.
57. Tondo, L., Baldessarini, RJ, Hennen, J., Floris, G. (1998) Lithium maintenance treatment of depression and mania in bipolar I and bipolar II disorders. Am J Psychiatry 155: 638-645.
58. Uvnas-Moberg, K. (1998) Oxytocin may mediate the benefits of positive social interaction and emotions. Psychoneuroendocrinology 23: 819-835.
59. Vandrey, R., Budney, AJ, Kamon, JL, Stanger, C. (2005) Cannabis withdrawal in adolescent treatment seekers. Drug Alcohol Depend 78: 205-210.
60. Vestergaard, P., Amdisen, A., Schou, M. (1980) Clinically significant side effects of lithium treatment. A survey of 237 patients in long-term treatment. Acta Psychiatr Scand 62: 193-200.